Nektar Therapeutics (NKTR) Non Operating Income (2010 - 2026)

Nektar Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$336000.0 for Q1 2026.

• In Q1 2026, Non Operating Income fell 226.32% year-over-year to -$336000.0; the TTM figure through Mar 2026 stood at -$241000.0 (up 98.71% YoY), while the FY2025 annual figure was $361000.0, up 102.58% from the prior year.
• Non Operating Income was -$336000.0 for Q1 2026 at Nektar Therapeutics, down from -$44000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $26.3 million in Q1 2022 to a low of -$13.7 million in Q4 2024.
• Historically, Non Operating Income has averaged $320117.6 across 5 years, with a median of -$99000.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income surged 1464.89% in 2022, then slumped 706.87% in 2024.
• A 5-year view of Non Operating Income shows it stood at $7.6 million in 2022, then sank by 265.82% to -$12.7 million in 2023, then declined by 8.48% to -$13.7 million in 2024, then soared by 99.68% to -$44000.0 in 2025, then plunged by 663.64% to -$336000.0 in 2026.
• The last three Non Operating Income figures came in at -$336000.0 (Q1 2026), -$44000.0 (Q4 2025), and -$121000.0 (Q3 2025), per Business Quant data.